Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964705 | 0.79 | PDPK1 (0.41) | PDPK1GDA | |
| SCHEMBL1251786 | 0.79 | — | — | |
| SCHEMBL5133438 | 0.77 | ADORA2A (0.55) | PDPK1GDA | |
| SCHEMBL6424961 | 0.77 | PNP (0.48) | PNP | |
| SCHEMBL2634662 | 0.77 | NUDT1 (0.61) | PDPK1GDA | |
| SCHEMBL1766004 | 0.77 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL6356987 | 0.77 | PNP (0.54) | PNP | |
| SCHEMBL1705024 | 0.77 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL4907123 | 0.77 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL16513157 | 0.77 | PDPK1 (0.44) | PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | claimed |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORP (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024192323-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2019227847-A1 | CHITOSAN-BASED IONIC CONDUCTIVE MATERIAL CONTAINING PURINE STRUCTURE AND PREPARATION METHOD THEREOF | 华南理工大学 (CN) | 2019-12-05 | — | — | WO | claimed |
| EP-4680228-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | Glaukos Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORP (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024192323-A2 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | GLAUKOS CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| CN-109036623-A | A kind of cellulose base ion conductive material of purine-containing structure and preparation method thereof | 华南理工大学 | 2018-12-18 | — | — | CN | disclosed |
| EP-2249874-A1 | METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS | ProSensa Holding BV (NL) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009099326-A1 | METHODS AND MEANS FOR TREATING DNA REPEAT INSTABILITY ASSOCIATED GENETIC DISORDERS | PROSENSA HOLDING BV (NL) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009079000-A1 | IMIDAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20050043268-A1 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2005-02-24 | — | — | US | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043268-A1 | Inhibition of viruses | RNASE1, HNRNPA1, RNASEH1 | PNP 132/4885PDPK1 4629/4885GDA 465/4885 |
| US-20240316028-A1 | OPHTHALMIC CREAM FORMULATIONS AND THEIR USES | PDE12, TBXA2R, PDE6G | PNP 2553/4885PDPK1 2635/4885GDA 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.